These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 21287250)
1. In vivo bioequivalence and in vitro similarity factor (f2) for dissolution profile comparisons of extended release formulations: how and when do they match? Duan JZ; Riviere K; Marroum P Pharm Res; 2011 May; 28(5):1144-56. PubMed ID: 21287250 [TBL] [Abstract][Full Text] [Related]
2. In vitro dissolution similarity factor (f2) and in vivo bioequivalence criteria, how and when do they match? Using a BCS class II drug as a simulation example. Xie F; Ji S; Cheng Z Eur J Pharm Sci; 2015 Jan; 66():163-72. PubMed ID: 25315411 [TBL] [Abstract][Full Text] [Related]
3. Statistical comparison of dissolution profiles to predict the bioequivalence of extended release formulations. Gomez-Mantilla JD; Schaefer UF; Casabo VG; Lehr T; Lehr CM AAPS J; 2014 Jul; 16(4):791-801. PubMed ID: 24854895 [TBL] [Abstract][Full Text] [Related]
4. Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based Biopharmaceutics Modeling and Bioequivalence Safe Space. Miranda Dos Santos E; Ferraz HG; Issa MG; Duque MD J Pharm Sci; 2023 Dec; 112(12):3131-3140. PubMed ID: 37473918 [TBL] [Abstract][Full Text] [Related]
5. Use of partial AUC to demonstrate bioequivalence of Zolpidem Tartrate Extended Release formulations. Lionberger RA; Raw AS; Kim SH; Zhang X; Yu LX Pharm Res; 2012 Apr; 29(4):1110-20. PubMed ID: 22278753 [TBL] [Abstract][Full Text] [Related]
6. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers. Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557 [TBL] [Abstract][Full Text] [Related]
7. Use of in vitro-in vivo correlation to predict the pharmacokinetics of several products containing a BCS class 1 drug in extended release matrices. Mirza T; Bykadi SA; Ellison CD; Yang Y; Davit BM; Khan MA Pharm Res; 2013 Jan; 30(1):179-90. PubMed ID: 22910891 [TBL] [Abstract][Full Text] [Related]
8. Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation. González-García I; García-Arieta A; Merino-Sanjuan M; Mangas-Sanjuan V; Bermejo M Eur J Pharm Sci; 2018 Jul; 119():200-207. PubMed ID: 29680456 [TBL] [Abstract][Full Text] [Related]
9. Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria. Shram MJ; Quinn AM; Chen N; Faulknor J; Luong D; Sellers EM; Endrenyi L Clin Ther; 2012 May; 34(5):1170-81. PubMed ID: 22512898 [TBL] [Abstract][Full Text] [Related]
10. Bioequivalence of two enteric coated formulations of pantoprazole in healthy volunteers under fasting and fed conditions. de Campos DR; Vieira NR; Bernasconi G; Barros FA; Meurer EC; Marchioretto MA; Coelho EC; Calafatti SA; Sommer C; Couto JM; Buranello S; Silva AR; Amarante AR; Abib E; Júnior JP Arzneimittelforschung; 2007; 57(6):309-14. PubMed ID: 17688075 [TBL] [Abstract][Full Text] [Related]
11. Bioequivalence evaluation of two brands of lisinopril tablets by in vitro comparative dissolution test and in vivo bioequivalence test. Shin MC; Kim JK; Kim CK Arzneimittelforschung; 2008; 58(1):11-7. PubMed ID: 18368945 [TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo equivalence of two oral atenolol tablet formulations. Cuadrado A; Rodríguez Gascón A; Hernández RM; Castilla AM; de la Maza A; López de Ocáriz A; Calvo B; Pedraz JL Arzneimittelforschung; 2002; 52(5):371-8. PubMed ID: 12087922 [TBL] [Abstract][Full Text] [Related]
13. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation. Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538 [TBL] [Abstract][Full Text] [Related]
14. Comparison of Dissolution Similarity Assessment Methods for Products with Large Variations: f Yoshida H; Shibata H; Izutsu KI; Goda Y Biol Pharm Bull; 2017; 40(5):722-725. PubMed ID: 28458360 [TBL] [Abstract][Full Text] [Related]
15. Influence of hydroxypropyl methylcellulose mixture, apparent viscosity, and tablet hardness on drug release using a 2(3) full factorial design. Khanvilkar KH; Huang Y; Moore AD Drug Dev Ind Pharm; 2002 May; 28(5):601-8. PubMed ID: 12098849 [TBL] [Abstract][Full Text] [Related]
16. Bioequivalence of tacrolimus formulations with different dynamic solubility and in-vitro dissolution profiles. Kwon M; Yeom D; Kim NA; Choi du H; Park J; Wang H; Yoo SD; Jeong SH Arch Pharm Res; 2015 Jan; 38(1):73-80. PubMed ID: 24627339 [TBL] [Abstract][Full Text] [Related]
17. Permutation Test (PT) and Tolerated Difference Test (TDT): two new, robust and powerful nonparametric tests for statistical comparison of dissolution profiles. Gómez-Mantilla JD; Casabó VG; Schaefer UF; Lehr CM Int J Pharm; 2013 Jan; 441(1-2):458-67. PubMed ID: 23194886 [TBL] [Abstract][Full Text] [Related]
18. In-vitro and in-vivo correlation for two gliclazide extended-release tablets. Mandal U; Ray KK; Gowda V; Ghosh A; Pal TK J Pharm Pharmacol; 2007 Jul; 59(7):971-6. PubMed ID: 17637192 [TBL] [Abstract][Full Text] [Related]
19. Interpretation and optimization of the dissolution specifications for a modified release product with an in vivo-in vitro correlation (IVIVC). Hayes S; Dunne A; Smart T; Davis J J Pharm Sci; 2004 Mar; 93(3):571-81. PubMed ID: 14762896 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and bioequivalence evaluation of 2 levosulpiride preparations after a single oral dose in healthy male Korean volunteers. Cho HY; Moon JD; Lee YB Int J Clin Pharmacol Ther; 2004 Mar; 42(3):174-80. PubMed ID: 15049438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]